The U.S. House of Representatives Committee on Energy and Commerce, Subcommittee on Health had planned a hearing on March 5, 2015, to review the functionality of the 340B Drug Pricing Program to understand how it impacts patients, providers, manufacturers, and other stakeholders.  The hearing, entitled “Examining the 340B Drug Pricing Program,” was postponed due to inclement weather last week in the D.C. area.  Information about the scheduled hearing, including a link to the Subcommittee’s background memo, is available by clicking here